Linja Marika J, Savinainen Kimmo J, Tammela Teuvo L J, Isola Jorma J, Visakorpi Tapio
Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere, Tampere, Finland.
Prostate. 2003 May 15;55(3):180-6. doi: 10.1002/pros.10242.
It has been suggested that estrogens and their receptors (ERs) may be involved in the development and progression of prostate cancer. To elucidate the significance of these receptors, expression of both ERalpha and ERbeta was measured in benign and malignant prostate tumors, as well as in cell lines.
Expression of ERalpha and ERbeta was measured in prostate hyperplasia (BPH, n = 7), androgen-dependent (n = 30) as well as hormone-refractory (n = 12) prostate carcinomas, and in four prostate cancer cell lines (LNCaP, DU145, PC-3, and 22Rv1) using real-time quantitative RT-PCR.
Only low-level expression of ERalpha was found in all tumor types and cell lines. The level of expression was similar to that observed in breast carcinomas found to be negative for ERalpha by immunohistochemistry. All cell lines showed low, but detectable, levels of ERbeta expression. The mean expression of ERbeta in the hormone-refractory carcinomas was about half that seen in BPH or the androgen-dependent carcinomas; however, the difference was not statistically significant.
The data suggest it is unlikely that alterations in the expression of either ER are commonly involved in the progression of prostate cancer.
有研究表明，雌激素及其受体（ERs）可能参与前列腺癌的发生和发展。为阐明这些受体的意义，我们检测了良性和恶性前列腺肿瘤以及细胞系中ERα和ERβ的表达。
采用实时定量逆转录聚合酶链反应（RT-PCR）检测前列腺增生（BPH，n = 7）、雄激素依赖型（n = 30）以及激素难治型（n = 12）前列腺癌，和四种前列腺癌细胞系（LNCaP、DU145、PC-3和22Rv1）中ERα和ERβ的表达。
在所有肿瘤类型和细胞系中均仅发现ERα低水平表达。其表达水平与免疫组化检测显示ERα阴性的乳腺癌中观察到的水平相似。所有细胞系均显示出低水平但可检测到的ERβ表达。激素难治型癌中ERβ的平均表达量约为BPH或雄激素依赖型癌中的一半；然而，差异无统计学意义。
数据表明，ER表达的改变通常不太可能参与前列腺癌的进展。
Zotero 插件